Xanthine Oxidase-Induced Inflammatory Responses in Respiratory Epithelial Cells: A Review in Immunopathology of COVID-19. (6th August 2021)

• Record Type: Journal Article
• Authors: Pratomo, Irandi Putra; Noor, Dimas R.; Kusmardi, Kusmardi; Rukmana, Andriansjah; Paramita, Rafika I.; Erlina, Linda; Fadilah, Fadilah; Gayatri, Anggi; Fitriani, Magna; Purnomo, Tommy T. H.; Ariane, Anna; Heryanto, Rudi; Tedjo, Aryo
• Other Names: Moshage Han J. Academic Editor.
• Is Part Of: International journal of inflammation. Volume 2021(2021)
• Publication Date: 2021-08-06
• Subjects: Inflammation -- Periodicals; Inflammation; Inflammation; Periodicals; 617.22
• DOI: 10.1155/2021/1653392
• Languages: English
• ISSNs: 2090-8040

Abstract

Abstract : Xanthine oxidase (XO) is an enzyme that catalyzes the production of uric acid and superoxide radicals from purine bases: hypoxanthine and xanthine and is also expressed in respiratory epithelial cells. Uric acid, which is also considered a danger associated molecule pattern (DAMP), could trigger a series of inflammatory responses by activating the inflammasome complex path and NF- κ B within the endothelial cells and by inducing proinflammatory cytokine release. Concurrently, XO also converts the superoxide radicals into hydroxyl radicals that further induce inflammatory responses. These conditions will ultimately sum up a hyperinflammation condition commonly dubbed as cytokine storm syndrome (CSS). The expression of proinflammatory cytokines and neutrophil chemokines may be reduced by XO inhibitor, as observed in human respiratory syncytial virus (HRSV)-infected A549 cells. Our review emphasizes that XO may have an essential role as an anti-inflammation therapy for respiratory viral infection, including coronavirus disease 2019 (COVID-19).